FindMyKOL

Daniel Flora, MD

Basic profile

St. Elizabeth Healthcare

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionEdgewood, KY · SoutheastSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Daniel Flora is an Oncology physician affiliated with St. Elizabeth Healthcare. OpenAlex indexes 44 publications with 2,790 citations (h-index 12).

Overview

Scholarship

indexed output and impact (OpenAlex)
44publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

2,790citations

Citations across these publications.

12h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
9companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • AstraZeneca
    Program year20251 paymentResearch
    $167,833
  • Merck & Co.
    Program year20251 paymentResearch
    $101,111
  • GSK
    Program year202518 paymentsResearch
    $19,701
All 26 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    29%
    Aromatase Inhibitor11.8%
    Anastrozole49%Letrozole43%Exemestane9%
    Part D<11 patients
    Kinase inhibitor4.5%
    Imatinib Mesylate48%Ibrance32%Sprycel20%
    Part D<11 patients

    + 7 more classes in this area

  • Nervous system

    22.6%
    Opioid Agonist5.5%
    Oxycodone-Acetaminophen48%Oxycodone Hcl35%Tramadol Hcl17%
    Part D<11 patients
    SNRI4.1%
    Duloxetine Hcl43%Venlafaxine Hcl Er35%Venlafaxine Hcl22%
    Part D<11 patients

    + 5 more classes in this area

  • Metabolism & gastrointestinal

    14.5%
    Corticosteroid5.5%
    Prednisone100%
    Part D≥22 patients
    Potassium supplement3.4%
    Potassium Chloride100%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”